Phase i study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 6, 2009, Pages 607-611

  Mahadevan, Daruka ^a   Dreisbach, Luke ^b   Kristedja, Timothy ^a   Williams, Debbie ^a   Obregon, Yrma ^a   Kurtin, Sandy ^a   Von Hoff, Daniel D ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b Desert Hematology Oncology Medical Group   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Dose limiting toxicity; Epirubicin; Fixed dose rate; Gemcitabine; Maximum tolerated dose

Indexed keywords

EPIRUBICIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPHYXIA; BILIRUBIN BLOOD LEVEL; BLADDER CANCER; BLADDER TUMOR; BONE MARROW; CHEST PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; HYPOTHESIS; KIDNEY ABSCESS; LEUKOPENIA; LIVER; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY TUMOR; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PROSTATE TUMOR; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMACH TUMOR; THROMBOCYTOPENIA; THYROID CANCER; THYROID TUMOR; TREATMENT RESPONSE; VOMITING; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73349100017     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819cc9ed     Document Type: Article

References (27)

1. Anderson H, Hopwood P, Stephens R, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small-cell lung Cancer. Br J Cancer. 2000;83:447-453.
2. Rini B, Vogelzang N, Dumas M, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419-2426.
3. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615-2619.
4. Ulrich-Pur H, Kornek G, Raderer M, et al. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer. 2000;88:2505-2511.
5. Burris H III, Moore M, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
6. Rothenberg M, Moore M, Cripps M, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347-353. (Pubitemid 26246785)
7. Wiernik P. Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas. J Clin Gastroenterol. 2000;30: 357-363.
8. Abbruzzese J, Grunewald R, Weeks E, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
9. Grunewald R, Abbruzzese J, Tarassoff P, et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27:258-262.
10. Veltkamp S, Beijnen J, Schellens J. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist. 2008;13:261-276.
11. Plunkett W, Huang P, Scarcy C, et al. Gemcitabine: preclinical pharmacology andmechanism of action. Semin Oncol. 1996;23(suppl 10):3-15.
12. Touroutoglou N, Gravel D, Raber M, et al. Clinical results of a pharmacodynamically- based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998;9:1003-1008.
13. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
14. Soo R, Wang L, Tham L, et al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol. 2006;17:1128-1133.
15. Kreil A, Bauer J, Scheithauer W. In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma. Acta Med Austriaca. 1999;26:93-100.
16. Kroep J, Pinedo H, van Groeningen C, et al. Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol. 1999;10(suppl 4):234-238.
17. Campone M, Fumoleau P, Viens P, et al. Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study. Breast. 2006;15: 601-609.
18. Andersson H, Friberg L, Horvath G, et al. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study. Acta Oncol. 1995;34:821-827.
19. Fetscher S, Brugger W, Engelhardt R, et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Ann Oncol. 1997;8:49-56. (Pubitemid 27112802)
20. Chi K, Chao Y, Chan W, et al. Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer. Br J Cancer. 1998;77:1984-1988.
21. Erol A, Ozgur S, Basar M, et al. Trial with bacillus Calmette-Guerin and epirubicin combination in the prophylaxis of superficial bladder cancer. Urol Int. 1994;52:69-72.
22. Hausmaninger H, Morack G, Heinrich B, et al. Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study. Am J Clin Oncol. 2004;27:429-435.
23. van Putten J, Eppinga P, Erjavec Z, et al. Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study. Br J Cancer. 2000;82:806-811.
24. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2. 0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47.
25. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
26. Poplin E, Levy D, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate infusion [FDR] ) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol. 2006;24 (18S, Part1):LBA4004.
27. Luftner D, Flath B, Akrivarkis C, et al. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Invest New Drugs. 1998;16:141-146.